TEMODAR
Total Payments
$2.3M
Transactions
47
Doctors
6
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $5,693 | 1 | 0 |
| 2021 | $265,714 | 1 | 0 |
| 2020 | $544,085 | 7 | 0 |
| 2019 | $930,609 | 9 | 0 |
| 2018 | $146,201 | 16 | 3 |
| 2017 | $373,196 | 13 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 28 | 99.9% |
| Travel and Lodging | $3,099 | 15 | 0.1% |
| Food and Beverage | $109.17 | 4 | 0.0% |
Payments by Type
Research
$2.3M
28 transactions
General
$3,208
19 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase I,II Study of T-DM1 alone versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | Merck Sharp & Dohme Corporation | $2.1M | 0 |
| Phase II study of epacadostat INCB024360 pembrolizumab MK-3475 in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies | Merck Sharp & Dohme Corporation | $81,222 | 0 |
| A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | Merck Sharp & Dohme Corporation | $73,892 | 0 |
| Phase I,II Study of T-DM1 alone versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | Merck Sharp & Dohme LLC | $5,693 | 0 |
Top Doctors Receiving Payments for TEMODAR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Stanford, CA | $2.3M | 28 |
| , MD | Neurology | Boston, MA | $1,719 | 4 |
| , MD | Radiation Oncology | Saint Louis, MO | $729.92 | 4 |
| David Reardon | Hematology & Oncology | Boston, MA | $477.03 | 6 |
| , MD, PHD | Radiation Oncology | Houston, TX | $237.76 | 3 |
| , MD, PHD | Internal Medicine | Boston, MA | $24.90 | 1 |
| , M.D | Pain Medicine | Houston, TX | $19.17 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $2.3M
- Merck Sharp & Dohme LLC $5,693
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 6
- Transactions 47
About TEMODAR
TEMODAR is a drug associated with $2.3M in payments to 6 healthcare providers, recorded across 47 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2023. In 2023, $5,693 was paid across 1 transactions to 0 doctors.
The most common payment nature for TEMODAR is "Unspecified" ($2.3M, 99.9% of total).
TEMODAR is associated with 4 research studies, including "Phase I,II Study of T-DM1 alone versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery" ($2.1M).